


IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the claims:

Claim 1 (**currently amended**): A method for the treatment of thrombosis and/or hypercoagulability in blood and/or tissues or prophylaxis of a disease or medical condition ~~wherein inhibition of carboxypepsidase U is beneficial~~, said method comprising administering to a warm-blooded animal in need thereof an effective amount of a compound of formula (I):



wherein:

X is $(\text{CH}_2)_m\text{Y}(\text{CH}_2)_n$;

m and n are, independently, 1, 2, 3, 4, 5 or 6; provided that m + n is not more than 6;

Y is a bond, O, $\text{S}(\text{O})_p$, or S-S;

R^1 is CO_2R^{15} or a carboxylic acid isostere;

R^2 , R^3 , R^4 , R^5 and R^6 are, independently, hydrogen, C_{1-6} alkyl (optionally substituted by halogen, hydroxy, cyano, SH, $\text{S}(\text{O})_3\text{H}$, $\text{S}(\text{O})_4(\text{C}_{1-6}$ alkyl), $\text{OC}(\text{O})(\text{C}_{1-4}$ alkyl), CF_3 , C_{1-4} alkoxy, OCF_3 , COOH , CONH_2 , $\text{CONH}(\text{C}_{1-6}$ alkyl), NH_2 , $\text{CNH}(\text{NH}_2)$, or $\text{NHCNH}(\text{NH}_2)$), C_{3-6} cycloalkyl(C_{1-4})alkyl (wherein the cycloalkyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3 , C_{1-4} alkoxy, OCF_3 , NH_2 , $\text{CNH}(\text{NH}_2)$ or $\text{NHCNH}(\text{NH}_2)$), heterocyclyl(C_{1-4})alkyl (wherein the heterocyclyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3 , C_{1-4} alkoxy, OCF_3 , NH_2 , $\text{CNH}(\text{NH}_2)$ or $\text{NHCNH}(\text{NH}_2)$), phenyl(C_{1-4})alkyl (wherein the phenyl ring is optionally substituted by halogen, hydroxy, cyano, C_{1-4} alkyl, CF_3 , C_{1-4} alkoxy, OCF_3 , NH_2 , $\text{CNH}(\text{NH}_2)$ or $\text{NHCNH}(\text{NH}_2)$) or heteroaryl(C_{1-4})alkyl (wherein the heteroaryl ring is

optionally substituted by halogen, hydroxy, cyano, C₁₋₄ alkyl, CF₃, C₁₋₄ alkoxy, OCF₃, NH₂, CNH(NH₂) or NHCNH(NH₂));

p and q are, independently, 0, 1 or 2;

R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³ are, independently, H or C₁₋₄ alkyl;

R¹⁴ is H or C₁₋₄ alkyl; and,

R¹⁵ is H or C₁₋₄ alkyl;

or a pharmaceutically acceptable salt thereof.

Claims 2-4 (**cancelled**).

Claim 5 (**previously presented**): The method of claim 1 wherein X is (CH₂)₄.

Claim 6 (**previously presented**): The method of claim 1 wherein R¹ is CO₂R¹⁵ in which R¹⁵ is H or C₁₋₄ alkyl.]

Claims 7-22 (**cancelled**).